Background: Previous research has reported evidence that patients with major depressive disorder (MDD) show anxiety symptoms and neurocognitive impairments. However, the influence of anxiety on neurocognitive function in MDD patients during antidepressant treatment is unclear. Method: MDD patients (n=164) completed a 12-week, multicenter, randomized trial assigned in a 1:1 ratio to either tianeptine or escitalopram. Changes of anxiety symptoms were assessed by the Hamilton Anxiety Rating Scale (HAM-A), and the Hamilton Depression Rating Scale (HAM-D), self-rated subjective cognitive impairment on memory and concentration, the MiniMental Status Examination (MMSE), Continuous Performance Test (CPT), Verbal Learning Test (VLT), and Raven's Progressive Matrices (RPM) were assessed every 4 weeks. Results: During 12 weeks of treatment, decrease in the HAM-A score was significantly associated with improvement of subjective cognitive impairments on memory (p<0.001) and concentration (p<0.001), and objective measures on delayed memory (p=0.006) and reasoning ability (p=0.002), after adjusting for covariates such as baseline HAM-A scores, time, sex, age, education years and assigned medication using the Mixed effects and Generalized Estimated Equation model analysis. However, the other cognitive outcome variables, immediate memory, commission error, and MMSE, which showed significant improvement through 12-week study period, showed no significant association with improvement of anxiety. Conclusion: Improvement of anxiety symptoms was significantly associated with improvement in subjective and objective neurocognitive functions such as delayed memory and reasoning ability in elderly MDD patients during antidepressant treatment, but not significantly associated with improvement of immediate memory and commission error.
among both American and East Asian patients with major depressive disorder (MDD). This study aimed to explore hypochondriasis and its correlates, using the Hamilton Depression Rating Scale (HAM-D), among American and Korean MDD outpatients of ages 18 and older. Consistent with previous crosscultural findings, Korean MDD patients exhibited significantly higher scores for hypochondriasis than Americans after controlling for total HAM-D scores and demographic variables (p<0.0001), even though American patients had significantly higher total HAM-D scores (p<0.0001). Whereas hypochondriasis appeared to be common among Koreans regardless of age, years of education, and employment status, Americans showed an increased tendency for hypochondriasis with greater age, fewer years of education, and unemployment. Despite the cultural differences, multivariate logistic regression analyses revealed that hypochondriasis is significantly associated with somatic anxiety (Koreans AOR=2.14, 95%CI 1.31-3.52; Americans AOR=1.98, 95%CI 1.69-2.31), suicide (Koreans AOR=0.42, 95%CI 0.24-0.74; Americans AOR=0.81, 95%CI 0.67-0.98), middle insomnia (Koreans AOR=1.95, 95%CI 1.18-3.23; Americans AOR=1.19, 95%CI 1.01-1.41), and psychic anxiety (Koreans AOR=1.62, 95%CI 1.00-2.61; Americans AOR=1.44, 95%CI 1.23-1.70) for both Korean and American MDD patients. Taken together, although hypochondriasis is more prevalent among Koreans, both Korean and American MDD patients with hypochondriacal symptoms appear to display high levels of somatic anxiety regardless of whether they experience actual physical symptoms. These findings suggest that both cultural and personal factors play a role in the presentation of hypochondriasis symptoms among Korean and American patients with MDD.
